[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Rajendra T, Lee KS, Leo KW, Kumar K, Chumpon C: Previously-treated nasopharyngeal carcinoma with cystic lesions in the temporal lobe. Singapore Med J; 2004 Dec;45(12):590-3
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Previously-treated nasopharyngeal carcinoma with cystic lesions in the temporal lobe.
  • First-line treatment consists primarily of radiotherapy and chemotherapy, with salvage surgery if recurrence occurs.
  • Patients with this tumours frequently present years after radiotherapy with symptomatic temporal lobe cystic lesions and a diagnostic problem arises.
  • A series of three cases of cystic temporal lobe lesions, with emphasis on their clinical, radiological and histopathological diagnostic aspects, are presented.
  • The methodology of both clinical and radiological diagnosis are presented.
  • [MeSH-major] Brain Abscess / diagnosis. Cysts / diagnosis. Nasopharyngeal Neoplasms / radiotherapy. Radiation Injuries / diagnosis. Temporal Lobe / pathology
  • [MeSH-minor] Adult. Aged. Brain Diseases / diagnosis. Brain Diseases / surgery. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15568122.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


2. Kurimoto M, Takaiwa A, Nagai S, Hayashi N, Endo S: Anomia for people's names after left anterior temporal lobe resection--case report. Neurol Med Chir (Tokyo); 2010 Jan;50(1):36-40
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anomia for people's names after left anterior temporal lobe resection--case report.
  • A 47-year-old man was admitted to our hospital with an intrinsic brain tumor in the left anterior temporal lobe.
  • Awake craniotomy was performed for dominant-hemispheric tumor resection using language mapping to identify the stimulation-induced positive language area.
  • The language area was detected on the superior temporal gyrus and preserved.
  • This case report and other sporadic cases with this type of deficit reveal the left anterior temporal lobe is an important brain area for retrieving people's names.
  • [MeSH-major] Anomia / etiology. Brain Neoplasms / complications. Glioblastoma / complications. Neurosurgical Procedures / adverse effects. Postoperative Complications / etiology. Temporal Lobe / pathology
  • [MeSH-minor] Brain Mapping. Craniotomy. Disability Evaluation. Dominance, Cerebral / physiology. Drug Therapy. Fatal Outcome. Humans. Language. Language Tests. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neuropsychological Tests. Preoperative Care. Radiotherapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098023.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Maruyama K, Morita A, Shibahara J, Nakazato Y, Kirino T: Multifocal pilocytic astrocytomas with ependymal differentiation in the bilateral medial temporal lobes: case report. Neurol Med Chir (Tokyo); 2005 Aug;45(8):411-4
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal pilocytic astrocytomas with ependymal differentiation in the bilateral medial temporal lobes: case report.
  • Neuroimaging showed bilateral temporal lobe masses with calcification and cysts.
  • The right temporal mass was subtotally resected.
  • The histological diagnosis was pilocytic astrocytoma with ependymal differentiation and a MIB-1 staining index of up to 8.0%.
  • Adjuvant chemotherapy consisting of carboplatin and vincristine was given followed by radiotherapy.
  • Neuroimaging showed that the bilateral tumors had disappeared and showed no recurrence for 29 months after the diagnosis.
  • Pilocytic astrocytoma usually presents as a solitary mass in the cerebellum or optic pathway with low proliferative activity, but should be included in the differential diagnosis of multifocal tumors arising in the bilateral temporal lobes.
  • Intensive treatment is recommended for patients with such specific neuroimaging and histological features.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Temporal Lobe / pathology
  • [MeSH-minor] Antibodies, Antinuclear. Antibodies, Monoclonal. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Proliferation. Child. Diagnosis, Differential. Ependyma / pathology. Hemianopsia / etiology. Hemianopsia / pathology. Hemianopsia / physiopathology. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neurosurgical Procedures. Paresis / etiology. Paresis / pathology. Paresis / physiopathology. Radiotherapy. Seizures / etiology. Seizures / pathology. Seizures / physiopathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127260.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / MIB-1 antibody
  •  go-up   go-down


Advertisement
4. Astner ST, Pihusch R, Nieder C, Rachinger W, Lohner H, Tonn JC, Molls M, Grosu AL: Extensive local and systemic therapy in extraneural metastasized glioblastoma multiforme. Anticancer Res; 2006 Nov-Dec;26(6C):4917-20
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive local and systemic therapy in extraneural metastasized glioblastoma multiforme.
  • Cases of extracranial metastases of glioblastoma multiforme to sites such as bones, spleen, lung, liver and kidneys have been reported but available information about treatment of organ and bone metastases is extremely scarce.
  • In this report a case of glioblastoma multiforme (GBM) of the temporal lobe with subsequent liver and bone metastases is described and the success of different chemotherapy regimens is discussed.
  • Two years after first diagnosis symptomatic local recurrence occurred.
  • As a result of relapse of liver metastases the patient received chemotherapy with adriamycin, cyclophosphamide and etoposide.
  • Visceral metastases were stable, but nevertheless the patient died from local progression 3 years after first diagnosis.
  • In conclusion, liver metastases of GBM can be effectively treated by chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Glioblastoma / drug therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214362.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


5. Jain R, Gujar S, McKeever P, Robertson P, Mukherji S: Imaging findings associated with childhood primary intracranial squamous cell carcinoma. AJNR Am J Neuroradiol; 2003 Jan;24(1):109-11
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 5-year-old girl with no preexisting systemic or CNS neoplasm presented with a large right temporal mass lesion, the histopathology of which proved to be a poorly differentiated adenosquamous carcinoma, a highly unusual primary intracranial tumor.
  • The tumor recurred despite radical resection, chemotherapy, and radiation therapy.
  • [MeSH-major] Brain Neoplasms / diagnosis. Carcinoma, Adenosquamous / diagnosis. Magnetic Resonance Imaging. Temporal Lobe. Tomography, X-Ray Computed
  • [MeSH-minor] Calcinosis / diagnosis. Calcinosis / pathology. Calcinosis / therapy. Child, Preschool. Combined Modality Therapy. Female. Humans. Magnetic Resonance Spectroscopy


6. Hiremath GK, Bingaman WE, Prayson RA, Nair D: Oligoastrocytoma presenting with intractable epilepsy. Epileptic Disord; 2007 Sep;9(3):315-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median age at diagnosis was 25 years (range 19-44 years).
  • Tumors arose from the left side in all patients and from the temporal lobe in five patients.
  • Median length of refractory epilepsy prior to surgery was 10.5 years (range 1-28 years), and the median number of antiepileptic drugs used was 2 (range 1-10).
  • There were no surgical complications, clinical or radiographic tumor recurrence at a mean follow up period of 3.2 years (range 2-8).
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Epilepsy / drug therapy. Epilepsy / etiology
  • [MeSH-minor] Adolescent. Adult. Anticonvulsants / therapeutic use. Craniotomy. Drug Resistance. Epilepsy, Complex Partial / etiology. Epilepsy, Complex Partial / surgery. Female. Humans. Magnetic Resonance Imaging. Male. Memory / physiology. Neoplasm Recurrence, Local. Neurosurgical Procedures. Temporal Lobe / pathology. Temporal Lobe / surgery

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884756.001).
  • [ISSN] 1294-9361
  • [Journal-full-title] Epileptic disorders : international epilepsy journal with videotape
  • [ISO-abbreviation] Epileptic Disord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


7. Kawataki T, Sato E, Sato T, Kinouchi H: Anaplastic ganglioglioma with malignant features in both neuronal and glial components--case report. Neurol Med Chir (Tokyo); 2010;50(3):228-31
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was subtotally removed, followed by irradiation and chemotherapy.
  • The histological diagnosis was anaplastic ganglioglioma.
  • Two months later, the tumor recurred with more pleomorphic appearance and higher cellularity with increased nestin expression level.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology. Intermediate Filament Proteins / metabolism. Neoplasm Proteins / metabolism. Nerve Tissue Proteins / metabolism. Neuroglia / pathology. Neurons / pathology
  • [MeSH-minor] Adult. Anaplasia. Fatal Outcome. Humans. Male. Neoplasm Recurrence, Local. Nestin. Seizures / etiology. Seizures / pathology. Temporal Lobe / cytology. Temporal Lobe / metabolism. Temporal Lobe / pathology

  • Genetic Alliance. consumer health - Ganglioglioma.
  • Genetic Alliance. consumer health - Anaplastic Ganglioglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339274.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


8. Guenther PP, Huebner A, Sobottka SB, Neumeister V, Weissbach G, Todt H, Parwaresch R: Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy. J Pediatr Hematol Oncol; 2001 Feb;23(2):134-8
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy.
  • An 8-year-old girl with an isolated cerebral mast cell tumor is presented.
  • Specific histopathologic stains were used to confirm the diagnosis detecting immunophenotype and proliferative activity.
  • Treatment with irradiation, intrathecal cytarabine, and interferon-alpha2b did not induce regression whereas polychemotherapy did.
  • Systemic combination chemotherapy led to marked transient tumor regression in this proliferating mast cell sarcoma in an unusual intracranial location.
  • [MeSH-major] Mast-Cell Sarcoma / drug therapy. Parietal Lobe / pathology. Supratentorial Neoplasms / drug therapy. Temporal Lobe / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Cytarabine / therapeutic use. Daunorubicin / administration & dosage. Disease Progression. Etoposide / administration & dosage. Fatal Outcome. Female. Headache / etiology. Humans. Immunologic Factors / therapeutic use. Injections, Spinal. Interferon-alpha / therapeutic use. Nausea / etiology. Neoplasm Recurrence, Local. Palliative Care. Papilledema / etiology. Prednisolone / administration & dosage. Radioisotope Teletherapy. Recombinant Proteins. Remission Induction. Treatment Failure. Vomiting / etiology

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11216707.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 99210-65-8 / interferon alfa-2b; 9PHQ9Y1OLM / Prednisolone; ZS7284E0ZP / Daunorubicin; DAV regimen
  •  go-up   go-down


9. Miura M, Iijima N, Hayashida K, Kitazawa K, Ishii K, Ohara S: [Case of leptomeningeal carcinomatosis effectively treated with intrathecal chemotherapy using ventriculoperitoneal shunt]. Rinsho Shinkeigaku; 2006 Jun;46(6):404-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of leptomeningeal carcinomatosis effectively treated with intrathecal chemotherapy using ventriculoperitoneal shunt].
  • Magnetic resonance imaging of the brain revealed meningeal thickening with enhancement.
  • The cerebrospinal fluid showed pleocytosis, high carcinoembryonic antigen (CEA) concentration, and presence of neoplastic cells, leading to the diagnosis of leptomeningeal carcinomatosis.
  • Systemic investigation for primary neoplasm identified a Bormman type 3 gastric cancer (papillary adenocarcinoma with micropapillary pattern).
  • For the next five months, he was well on oral S-1 and monthly intrathecal chemotherapy, being able to walk using a walker and to stay at home.
  • He subsequently developed posterior cortical symptoms such as prosopagnosia and cortical blindness and gradually lapsed into coma.
  • In the brain, leptomeningeal carcinomatosis involved the occipital lobes, the base of the temporal lobe, and the cerebellum.
  • We suggest that intrathecal chemotherapy using ventriculoperitoneal shunt with programmable valve system could be an effective method for the treatment of meningeal carcinomatosis.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / secondary. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / secondary. Ventriculoperitoneal Shunt
  • [MeSH-minor] Administration, Oral. Aged. Drug Combinations. Fatal Outcome. Humans. Injections, Spinal. Intracranial Hypertension / etiology. Intracranial Hypertension / therapy. Male. Methotrexate / administration & dosage. Oxonic Acid / administration & dosage. Stomach Neoplasms / pathology. Tegafur / administration & dosage. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16986702.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshō shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Lichy MP, Bachert P, Henze M, Lichy CM, Debus J, Schlemmer HP: Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy. Neuroradiology; 2004 Feb;46(2):126-9
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy.
  • We demonstrate the clinical value of MR spectroscopy in monitoring chemotherapy in a patient with recurrent glioma after stereotactic radiotherapy.
  • Diagnostic imaging before and after chemotherapy included contrast-enhanced MRI, single-voxel proton MR spectroscopy ((1)H MRS), (1)H MR spectroscopic imaging ((1)H SI), and fluorodeoxyglucose (FDG) positron-emission tomography (PET).
  • A significant decrease in choline signal intensity was observed 2 months after chemotherapy indicating tumour chemosensitivity, in line with tumour shrinkage on MRI and decreased uptake of FDG.
  • Assessment of early response by MRS may help to improve treatment protocols in other patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aspartic Acid / analogs & derivatives. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Energy Metabolism / drug effects. Image Processing, Computer-Assisted. Magnetic Resonance Spectroscopy. Neoplasm Recurrence, Local / drug therapy. Radiosurgery. Temporal Lobe / drug effects
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Choline / metabolism. Creatine / metabolism. Humans. Lomustine / administration & dosage. Male. Neurologic Examination / drug effects. Procarbazine / administration & dosage. Tomography, Emission-Computed. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2001 Aug;22(7):1316-24 [11498420.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] Magn Reson Med. 2001 Aug;46(2):228-39 [11477625.001]
  • [Cites] J Magn Reson Imaging. 1999 Aug;10(2):130-7 [10441015.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Jan;20(1):117-23 [9974066.001]
  • [Cites] J Nucl Med. 2000 Nov;41(11):1861-7 [11079496.001]
  • [Cites] Magn Reson Med. 1998 Dec;40(6):822-31 [9840826.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):306-18 [10690719.001]
  • [Cites] Nat Med. 1996 Mar;2(3):323-5 [8612232.001]
  • (PMID = 14685797.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 30KYC7MIAI / Aspartic Acid; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


11. Fischer M, Stüben G, Klahold M, Stuschke M, Budach V, Sack H, Jahnke K: Accelerated hyperfractionated radiotherapy with concurrent chemotherapy in locally advanced nasopharyngeal carcinoma: a phase II study. J Cancer Res Clin Oncol; 2001 Aug;127(8):507-11
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated hyperfractionated radiotherapy with concurrent chemotherapy in locally advanced nasopharyngeal carcinoma: a phase II study.
  • However, standardised therapeutical regimes are required in the treatment of these tumours.
  • METHODS: Between August 1990 and December 1997, 25 patients with stage III and IV nasopharyngeal carcinoma received an accelerated and hyperfractionated radiotherapy with concurrent chemotherapy (5-FU and mitomycin C).
  • The primary tumour and positive lymph nodes received a total dose of 72 Gy over a period of 6 weeks.
  • In the first 3 weeks, irradiation fields were treated five times per week with 2 Gy per fraction.
  • Thereafter, treatment was accelerated, giving two daily fractions of 1.4 Gy.
  • No severe late complications such as blindness or temporal lobe necrosis were observed.
  • CONCLUSIONS: The presented data are promising and show that the combination of hyperfractionated accelerated radiotherapy and chemotherapy is feasible and effective.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Dose Fractionation. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Radiotherapy, Adjuvant. Salvage Therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11501751.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Hirth A, Pedersen PH, Wester K, Mörk S, Helgestad J: Cerebral atypical teratoid/rhabdoid tumor of infancy: long-term survival after multimodal treatment, also including triple intrathecal chemotherapy and gamma knife radiosurgery--case report. Pediatr Hematol Oncol; 2003 Jun;20(4):327-32
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral atypical teratoid/rhabdoid tumor of infancy: long-term survival after multimodal treatment, also including triple intrathecal chemotherapy and gamma knife radiosurgery--case report.
  • The patient was a 1 year-old boy presenting with a large AT/RT in the right temporal lobe.
  • He was treated with complete surgery, followed by multiagent chemotherapy.
  • Later he had a second resection and intrathecal chemotherapy and Gamma knife radiosurgery was added to the treatment.
  • Except for a well-controlled temporal epilepsy, the boy is doing well after 6 years follow-up.
  • Intrathecal chemotherapy and Gamma knife radiosurgery of single recurrent or residual tumors might increase survival.
  • [MeSH-major] Brain Neoplasms / therapy. Rhabdoid Tumor / therapy. Teratoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Infant. Injections, Spinal. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Radiosurgery. Survivors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12746165.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Biassoni V, Casanova M, Spreafico F, Gandola L, Massimino M: A case of relapsing glioblastoma multiforme responding to vinorelbine. J Neurooncol; 2006 Nov;80(2):195-201
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Childhood malignant gliomas are rare and their clinical behavior is almost as aggressive as in adults: they resist treatment, progress rapidly and often spread.
  • Therapeutic strategies at relapse deserve an experimental approach, since none of the conventional-dose treatments have demonstrated a clear superiority over the others and no randomized trials have proved that high-dose chemotherapy is better than conventional treatment.
  • Vinorelbine is a semi-synthetic vinca alkaloid with an in vitro and in vivo experimentally proven broad spectrum of activity, including against malignant brain glioma.
  • We report our experience with a 19-year-old girl with glioblastoma multiforme (GBM) of the deep temporal region recurring 6 months after completing an intensive treatment that included preradiation chemotherapy (chemotherapy as a preradiation "sandwich" phase) with a myeloablative course of thiotepa, tumor bed radiotherapy and postradiation maintenance chemotherapy.
  • This case report suggests that vinorelbine is effective against high-grade pediatric glioma and, since this evidence has only one precedent in the literature (and given the generally poor prognosis for this tumor), even this single success seems worth reporting.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / therapeutic use. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Temporal Lobe / pathology. Thiotepa / therapeutic use

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1998;42(6):479-82 [9788574.001]
  • [Cites] Semin Oncol. 1989 Apr;16(2 Suppl 4):2-4 [2540531.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] Neurosurg Focus. 2003 Feb 15;14(2):e1 [15727422.001]
  • [Cites] Neurosurgery. 1987 Mar;20(3):416-20 [3574617.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1664-71 [15378498.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2771-8 [2160318.001]
  • [Cites] J Neurosurg. 1981 Dec;55(6):917-21 [6271933.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):397-409 [11139371.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3263-8 [12115359.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Feb;25(2):201-9 [14970018.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):72-7 [10413158.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2131-7 [11066055.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):41-8 [15701281.001]
  • (PMID = 16670944.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; 905Z5W3GKH / Thiotepa; Q6C979R91Y / vinorelbine
  •  go-up   go-down


14. Newton HB, Stevens C, Santi M: Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report. J Neurooncol; 2001 Dec;55(3):179-84
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report.
  • Fallopian tube carcinoma is the least common neoplasm of the female genital tract.
  • Although rare, neurological complications such as brain metastases can develop.
  • It remains unclear, however, what role chemotherapy has in the treatment of these patients and what route of administration is most effective.
  • Intra-arterial (IA) regional administration of chemotherapy may increase intra-tumoral drug concentrations and improve efficacy.
  • We report the case of a 47-year-old woman who developed bilateral fallopian tube cancer and multifocal brain metastases.
  • After progression through radiation therapy and oral chemotherapy, she was placed on IA carboplatin (200 mg/m2/d x 2 days every 4 weeks) and intravenous etoposide (100 mg/m2/d x 2 days every 4 weeks).
  • During treatment she had objective tumor shrinkage that has remained stable for more than 12 months.
  • For patients with fallopian tube carcinoma that develop brain metastases and respond poorly to surgery and/or irradiation, multi-agent chemotherapy containing carboplatin should be considered.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Brain Stem / pathology. Fallopian Tube Neoplasms / pathology. Temporal Lobe / pathology
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Carboplatin / administration & dosage. Carotid Arteries. Cisplatin / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Cyclophosphamide / administration & dosage. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Etoposide / administration & dosage. Fallopian Tubes / injuries. Female. Humans. Infusions, Intra-Arterial. Infusions, Intravenous. Magnetic Resonance Imaging. Middle Aged. Paclitaxel / administration & dosage. Physical Examination / adverse effects. Rupture, Spontaneous. Vertebral Artery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Pharmacother. 1999 Jul-Aug;33(7-8):816-32 [10466912.001]
  • [Cites] Oncology (Williston Park). 1989 Oct;3(10):20-6; discussion 26-7, 30, 32 [2701210.001]
  • [Cites] Radiology. 1999 Oct;213(1):135-40 [10540653.001]
  • [Cites] Med Oncol. 1998 Apr;15(1):6-14 [9643524.001]
  • [Cites] Am Fam Physician. 1999 Feb 15;59(4):878-86 [10068711.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1553-60 [1383433.001]
  • [Cites] Expert Opin Investig Drugs. 2000 Dec;9(12):2815-29 [11093355.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):637-47 [10649259.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):71-6 [9422560.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1599-605 [10193952.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):972-80 [1735089.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):527-36 [8823780.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2076-84 [11066048.001]
  • (PMID = 11859973.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16058
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; YF1K15M17Y / temozolomide
  •  go-up   go-down


15. Beaumont TL, Kupsky WJ, Barger GR, Sloan AE: Gliosarcoma with multiple extracranial metastases: case report and review of the literature. J Neurooncol; 2007 May;83(1):39-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliosarcoma is a rare malignant neoplasm of the central nervous system with a propensity for metastasis.
  • Here we describe the case of a 47-year-old man who developed pervasive extracranial metastases from a temporal gliosarcoma following radio- and chemotherapy for a primary glioblastoma.
  • The patient initially declined chemotherapy.
  • The tumor recurred twice and the patient underwent re-operation and multiple courses of chemotherapy; histopathological diagnosis remained glioblastoma multiforme.
  • The histogenesis and the potential role of therapeutic irradiation in the development of gliosarcoma are briefly reviewed.
  • [MeSH-major] Brain Neoplasms / pathology. Gliosarcoma / secondary. Liver Neoplasms / secondary. Neoplasms, Second Primary. Splenic Neoplasms / secondary. Temporal Lobe. Thoracic Neoplasms / secondary
  • [MeSH-minor] Chemotherapy, Adjuvant. Craniotomy. Fatal Outcome. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Glioblastoma / surgery. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Stereotaxic Techniques

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1976 Oct;45(4):398-408 [956876.001]
  • [Cites] Cancer. 1969 Aug;24(2):270-6 [4307749.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2910-8 [7773942.001]
  • [Cites] Neuroradiology. 2001 Jul;43(7):555-8 [11512585.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3761-7 [9850019.001]
  • [Cites] Arch Pathol. 1972 Jan;93(1):26-31 [5006996.001]
  • [Cites] Hum Pathol. 1997 Oct;28(10):1166-79 [9343324.001]
  • [Cites] Cancer. 1991 May 1;67(9):2342-9 [1849447.001]
  • [Cites] Acta Neuropathol. 1993;85(2):222-6 [8382897.001]
  • [Cites] Cancer. 1987 Apr 15;59(8):1506-8 [3545441.001]
  • [Cites] Pathology. 1984 Apr;16(2):217-21 [6087260.001]
  • [Cites] Clin Neuropathol. 2001 Sep-Oct;20(5):212-8 [11594506.001]
  • [Cites] Zentralbl Neurochir. 1980;41(1):57-68 [6258355.001]
  • [Cites] Surg Neurol. 1985 Dec;24(6):641-5 [2997942.001]
  • [Cites] Am J Pathol. 1955 Jul-Aug;31(4):633-53 [14388124.001]
  • [Cites] J Clin Oncol. 1999 May;17 (5):1516-25 [10334539.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 May-Jun;12(3):554-6 [2058514.001]
  • [Cites] Acta Neuropathol. 1996 Nov;92(5):515-9 [8922064.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):413-8 [4047352.001]
  • [Cites] Cancer. 1989 Feb 1;63(3):518-23 [2643455.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1510-8 [3476182.001]
  • [Cites] Acta Neuropathol. 1985;67(3-4):201-10 [4050334.001]
  • [Cites] J Neuropathol Exp Neurol. 1996 Sep;55(9):973-81 [8800093.001]
  • [Cites] J Neurosurg. 1984 Sep;61(3):599-601 [6747700.001]
  • [Cites] J Neurosurg. 1998 Sep;89(3):425-30 [9724117.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):425-32 [10666371.001]
  • [Cites] J Neuropathol Exp Neurol. 1992 Sep;51(5):493-8 [1381414.001]
  • [Cites] Cancer. 1958 Sep-Oct;11(5):888-94 [13585341.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] Acta Neuropathol. 1986;69(1-2):23-7 [3962596.001]
  • [Cites] Neurol Med Chir (Tokyo). 1989 Oct;29(10):938-43 [2482946.001]
  • [Cites] Acta Neuropathol. 1994;88(5):420-5 [7847070.001]
  • [Cites] Cancer. 1955 Jan-Feb;8(1):161-71 [13231048.001]
  • [Cites] Brain Pathol. 1999 Apr;9(2):421-2 [10219754.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Sep;54(5):651-6 [7666053.001]
  • [Cites] Ann Neurol. 1978 Sep;4(3):229-33 [214026.001]
  • [Cites] AMA Arch Pathol. 1958 Oct;66(4):536-49 [13582394.001]
  • [Cites] Surg Neurol. 2000 Nov;54(5):373-8; discusiion 378-9 [11165614.001]
  • (PMID = 17171442.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA101954
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


16. Teschner M, Lenarz T, Stöver T: [The interesting case -- case number 61]. Laryngorhinootologie; 2004 Jul;83(7):470-2
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 58-year-old patient presented after having undergone radiation therapy, afterloading therapy and chemotherapy of a T4 nasopharynx carcinoma.
  • The samples taken from the nasopharynx and the left maxillary sinus confirmed this diagnosis.
  • Neuroradiological imaging showed that the tumour extended into the area around the left skull base and also revealed an irregular formation located in the left temporal flap.
  • Therefore not only tumour resection (Fisch approach type C) but also a temporal craniotomy was indicated in order to determine the degree of intracerebral tumour extension.
  • The dura mater, which had been intact, was intraoperatively opened and revealed vital brain tissue, i. e. tumour infiltration had not reached the brain.
  • It was concluded that the radiological findings probably indicated a postradiogenic necrosis of the temporal flap.
  • The presented case illustrates the rare differential diagnostic procedure carried out in a patient with radiogenic necrosis while taking into account the possibility of local tumour infiltration into the brain parenchyma.
  • [MeSH-major] Brachytherapy. Magnetic Resonance Imaging. Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiation Injuries / diagnosis. Temporal Lobe / radiation effects
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged. Neoplasm Invasiveness. Skull Base Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15257498.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Watanabe W, Kuwabara R, Nakahara T, Hamasaki O, Sakamoto I, Okada K, Minamoto A, Mishima HK: Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas. Graefes Arch Clin Exp Ophthalmol; 2002 Dec;240(12):1033-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood.
  • With current treatment regimens including combined surgery, radiation and chemotherapy, the average life expectancy of the patients is limited to approximately 1 year.
  • Therefore, patients with glioblastoma sometimes have intracarotid injection of carcinostatics added to the treatment regimen.
  • CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Blindness / chemically induced. Brain Neoplasms / drug therapy. Carboplatin / adverse effects. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Orbital Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12483326.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


18. Ducray F, Colin P, Cartalat-Carel S, Pelissou-Guyotat I, Mahla K, Audra P, Gaucherand P, Honnorat J, Trouillas P: [Management of malignant gliomas diagnosed during pregnancy]. Rev Neurol (Paris); 2006 Mar;162(3):322-9
Hazardous Substances Data Bank. Fotemustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Prise en charge des gliomes malins découverts au cours d'une grossesse.
  • In post-partum additional treatment with chemotherapy was started.
  • In post-partum additional treatment with radiotherapy and chemotherapy was started.
  • Two weeks after surgery the patient's neurological condition worsened and in agreement with the patient a therapeutic abortion was decided.
  • Afterwards additional treatment with radiotherapy and chemotherapy was started.
  • The last patient received combined treatment with radiotherapy and chemotherapy for local recurrence of a mesencephalic high-grade glioma.
  • A posteriori it was discovered that the patient was at 4 months' gestation during this treatment.
  • Their pregnancy should not prevent them from receiving the best treatment for their glioma.
  • Treatment will depend upon clinico-radiological presentation, histology, gestational age and the patient's desires.
  • After the first trimester of gestation this treatment can be given without any important risks for the child.
  • [MeSH-major] Case Management. Glioblastoma / therapy. Pregnancy Complications, Neoplastic / therapy. Supratentorial Neoplasms / therapy
  • [MeSH-minor] Abortion, Therapeutic. Adrenal Cortex Hormones / therapeutic use. Adult. Algorithms. Anesthesia, General. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carbamazepine / therapeutic use. Carmustine / administration & dosage. Cesarean Section. Chemotherapy, Adjuvant. Cranial Irradiation. Craniotomy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Frontal Lobe. Humans. Infant, Newborn. Intracranial Hypertension / etiology. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Nitrosourea Compounds / administration & dosage. Nitrosourea Compounds / therapeutic use. Organophosphorus Compounds / administration & dosage. Organophosphorus Compounds / therapeutic use. Paresis / drug therapy. Paresis / etiology. Prednisolone / therapeutic use. Pregnancy. Prenatal Exposure Delayed Effects. Radiotherapy, Adjuvant. Remission Induction. Temporal Lobe

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CARBAMAZEPINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rev Neurol (Paris). 2006 Mar;162(3):293-4 [16585883.001]
  • (PMID = 16585887.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; 33CM23913M / Carbamazepine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9PHQ9Y1OLM / Prednisolone; GQ7JL9P5I2 / fotemustine; U68WG3173Y / Carmustine
  •  go-up   go-down


19. Tsuboi Y, Kurimoto M, Nagai S, Kamiyama H, Endo S: Malignant transformation of oligoastrocytoma: a case report. Brain Tumor Pathol; 2007;24(2):63-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of oligoastrocytoma resembling dysembryoplastic neuroepithelial tumor (DNT) with malignant transformation.
  • Magnetic resonance imaging (MRI) revealed an extensive left temporal lobe tumor.
  • She underwent partial resection of the tumor under awake surgery, while preserving her language function.
  • The surgical specimen showed that the majority of the tumor was composed of a glioneuronal element.
  • Therefore, our first pathological diagnosis was oligoastrocytoma and DNT.
  • She then underwent radiation therapy.
  • The tumor recurred at the left temporal lobe in June 2005.
  • The pathological diagnosis was anaplastic oligoastrocytoma with a MIB-1 staining index of 79%.
  • She received PAV (procarvazine, ACNU, and vincristine) chemotherapy, and the tumor subsided transiently.
  • The authors concluded that this tumor could be a malignant transformation of oligoastrocytoma mimicking DNT, and we wish to give warning that the presence of a glioneuronal component is not an absolute benign hallmark.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology. Neuroectodermal Tumors, Primitive / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Transformation, Neoplastic. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Neurosurgical Procedures. Radiotherapy

  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095133.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Stevens QE, Howes G, Dickerman RD, Lee JM, Nardone EM: Ganglioglioma occurring with glioblastoma multiforme: separate lesions or the same lesion? Clin Neurol Neurosurg; 2007 Feb;109(2):195-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gangliogliomas are frequently encountered in children and young adults and have a predilection for the temporal lobes.
  • Two separate lesions located in the posterior and anterior temporal lobes were found on imaging.
  • At initial surgery, she underwent gross total resection of the anterior temporal tip ganglioglioma and cyst aspiration of the posterior temporal lobe lesion.
  • The anterior temporal lesion was a ganglioglioma and did not recur.
  • However, the posterior temporal lesion was identified as a malignant ganglioglioma/glioblastoma multiforme variant that recurred multiple times requiring several surgeries, radiation and chemotherapy.
  • The occurrence of these distinct entities is uncommon in patients without a history of prior radiation treatment.
  • For benign gangliogliomas, gross total resection can be curative; however, more aggressive variants may be resistant to multimodal therapies.
  • [MeSH-major] Brain Neoplasms / surgery. Ganglioglioma / surgery. Glioblastoma / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Multiple Primary / surgery. Temporal Lobe / surgery
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytes / pathology. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Dose Fractionation. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neuroglia / pathology. Neurologic Examination. Radiotherapy, Adjuvant. Reoperation

  • Genetic Alliance. consumer health - Ganglioglioma.
  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056178.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


21. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D, Hadani M, Ram Z: Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg; 2004 Mar;100(3):472-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study.
  • OBJECT: A minority of patients with recurrent glioblastomas multiforme (GBMs) responds to systemic chemotherapy.
  • The patients were observed daily by performing diffusion-weighted (DW) magnetic resonance (MR) imaging to assess the convective process and routine diagnostic MR imaging to identify the tumor response.
  • Effective convection was determined by the progression of the hyperintense signal within the tumor on DW MR images, which corresponded to a subsequent lytic tumor response displayed on conventional MR images.
  • The antitumor effect was confirmed by one biopsy and three en bloc resections of tumors, which showed a complete response, and by one tumor resection, which demonstrated a partial response.
  • Lack of convection and a poor tumor response was associated with leakage of the convected drug into the subarachnoid space, ventricles, and cavities formed by previous resections, and was seen in tumors containing widespread necrosis.
  • CONCLUSIONS: On the basis of our data we suggest that CED of paclitaxel in patients with recurrent malignant gliomas is associated with a high antitumor response rate, although it is associated with a significant incidence of treatment-associated complications.
  • Diffusion-weighted MR images may be used to predict a response by demonstrating the extent of convection during treatment.
  • Optimization of this therapeutic approach to enhance its efficacy and reduce its toxicity should be explored further.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Convection. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / administration & dosage
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Diffusion Magnetic Resonance Imaging. Dose-Response Relationship, Drug. Female. Frontal Lobe / pathology. Frontal Lobe / surgery. Glioblastoma / drug therapy. Glioblastoma / pathology. Glioblastoma / surgery. Humans. Male. Middle Aged. Parietal Lobe / pathology. Parietal Lobe / surgery. Prospective Studies. Temporal Lobe / pathology. Temporal Lobe / surgery

  • Genetic Alliance. consumer health - Glioma.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15035283.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


22. Shim KW, Kim DS, Choi JU: Mixed or metachronous germ-cell tumor? Childs Nerv Syst; 2007 Jun;23(6):713-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed or metachronous germ-cell tumor?
  • OBJECTIVE AND IMPORTANCE: We report the extremely rare occurrence of a second germ-cell tumor at a different site and with different histological types long after total resolution of a pineal germinoma.
  • Neuroradiological studies revealed a tumor in the pineal region.
  • The tumor was biopsied with endoscope, and third ventriculostomy was performed.
  • Histologically, the tumor proved to be a germinoma.
  • The patient received 3 cycles of combination chemotherapy consisting of carboplatin and etoposide with radiotherapy.
  • The tumor was totally resolute.
  • Neuroradiological studies showed a tumor in the right temporal lobe.
  • INTERVENTION: The second tumor was totally removed.
  • Histologically, the tumor proved to be a mixed germ-cell tumor, which consisted a yolk-sac tumor and a germinoma.
  • After the second course of chemotherapy, magnetic resonance image studies revealed no evidence of the tumor.
  • CONCLUSION: The second tumor was considered to be a metachronous neoplasm rather than a recurrence of the original mixed germ-cell tumor, which consisted a yolk-sac tumor and a germinoma.
  • [MeSH-major] Brain Neoplasms / pathology. Endodermal Sinus Tumor / pathology. Germinoma / pathology. Neoplasms, Multiple Primary / pathology. Pinealoma / pathology. Temporal Lobe / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1985 Aug;63(2):155-67 [2991485.001]
  • [Cites] J Neurosurg. 1983 Nov;59(5):879-83 [6619943.001]
  • [Cites] Neurosurgery. 2002 Mar;50(3):613-6; discussion 616-7 [11841731.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):229-45 [8270446.001]
  • [Cites] Surg Neurol. 1990 Nov;34(5):336-42 [2218855.001]
  • [Cites] Neurosurgery. 1994 Oct;35(4):615-20; discussion 620-1 [7528902.001]
  • [Cites] Cancer. 1988 Sep 1;62(5):985-8 [3409178.001]
  • [Cites] Br J Neurosurg. 1995;9(3):391-401 [7546360.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] Pediatr Surg Int. 1997;12(1):24-7 [9035204.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):545-51 [1848284.001]
  • [Cites] Radiology. 2001 Feb;218(2):452-6 [11161161.001]
  • [Cites] Childs Brain. 1977;3(4):230-7 [891304.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):511-5 [9112446.001]
  • [Cites] Pediatr Neurosurg. 1994;21(1):91-103; discussion 104 [7947318.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):915-23 [9276355.001]
  • [Cites] Surg Neurol. 1992 Aug;38(2):114-20 [1509343.001]
  • [Cites] Acta Neuropathol. 1973;25(4):291-306 [4356228.001]
  • [Cites] Acta Neurochir (Wien). 1980;53(1-2):87-98 [7435285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):419-26 [9308946.001]
  • (PMID = 17187270.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Schmid I, Stachel D, Graubner UB, Elsner R, Schulze S, Pöllinger B, Goetz C, Haas RJ: [Supratentorial primitive neuroectodermal tumor: a single center experience and comparison with the literature]. Klin Padiatr; 2005 May-Jun;217(3):153-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Supratentorial primitive neuroectodermal tumor: a single center experience and comparison with the literature].
  • [Transliterated title] Supratentorieller primitiver neuroektodermaler Tumor: Erfahrungen in einem Zentrum im Vergleich zur Literatur.
  • All had craniospinal irradiation and chemotherapy according to the HIT-91 protocol.
  • The two children with incomplete resection died due to tumor progression after 7 and 10 months.
  • Two of the 4 children with complete tumor resection had local relapses 8 months after diagnosis and died after 14 and 18 months.
  • One child had a diffuse meningeal relapse 12 months after diagnosis.
  • Despite (high-dose) systemic chemotherapy and intraventricular mafosfamide, he died 21 months after diagnosis due to tumor although remission could be achieved.
  • Only one child is still in remission 86 months after diagnosis.
  • [MeSH-major] Brain Neoplasms. Cerebellar Nuclei. Corpus Callosum. Frontal Lobe. Neuroectodermal Tumors. Occipital Lobe. Parietal Lobe. Temporal Lobe. Thalamus
  • [MeSH-minor] Brain Stem Neoplasms / secondary. Cerebellar Neoplasms / mortality. Cerebellar Neoplasms / surgery. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Humans. Male. Mesencephalon. Neoplasm Recurrence, Local. Prognosis. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Supratentorial primitive neuroectodermal tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858707.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Baker MJ, Brem S, Daniels S, Sherman B, Phuphanich S: Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate. J Neurooncol; 2002 Sep;59(3):239-42
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite its biological activity in vitro, there have not been any prior reports of efficacy in the treatment of human malignant gliomas.
  • The patient initially presented with seizures caused by a biopsy-proven anaplastic astrocytoma of the frontal lobe.
  • The patient was treated with radiation therapy and Procarbazine-CCNU-Vincristine (PCV).
  • However, the tumor progressed and extended to the corpus callosum with midline shift, refractory to four cycles of continuous 72-h infusion of BCNU/Cisplatinum.
  • Additional enhancing lesions appeared in the left frontal and left temporal lobes.
  • Phenylbutyrate is a well-tolerated, oral agent that shows potential for the treatment of malignant gliomas.
  • Further studies should be considered to identify a subset of patients that have tumors sensitive to phenylbutyrate, either as a single agent or in combination with radiation therapy or other chemotherapeutic agents.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Phenylbutyrates / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Lomustine / therapeutic use. Magnetic Resonance Imaging. Procarbazine / therapeutic use. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurooncol. 2004 Jan;66(1-2):251; author reply 251 [15015793.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):891-5 [8313377.001]
  • [Cites] Adv Exp Med Biol. 1997;400A:501-5 [9547596.001]
  • [Cites] Cancer Control. 1998 Mar;5(2):107-114 [10761021.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):681-92 [10690554.001]
  • [Cites] Anticancer Res. 2001 Sep-Oct;21(5):3541-50 [11848521.001]
  • [Cites] Mayo Clin Proc. 1999 Feb;74(2):137-45 [10069350.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):984-90 [10071293.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1755-62 [9815560.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):97-108 [9524087.001]
  • [Cites] Nature. 2002 Jan 24;415(6870):436-42 [11807556.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Cancer Control. 1999 Oct;6(5):436-458 [10758576.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2932-8 [7773944.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2923-7 [8187079.001]
  • (PMID = 12241121.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / UO1 CA 76614
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Phenylbutyrates; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7WY7YBI87E / 4-phenylbutyric acid; PCV protocol
  •  go-up   go-down


25. Prayson RA, Abramovich CM: Glioneuronal tumor with neuropil-like islands. Hum Pathol; 2000 Nov;31(11):1435-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioneuronal tumor with neuropil-like islands.
  • Recently, an unusual glioneuronal tumor arising in adults marked histologically by neuropil-like islands was described.
  • We present a similar case arising in a 23-year-old woman who presented with headaches and seizures and on imaging studies was noted to have a frontal-temporal lobe mass.
  • The patient underwent partial resection of the tumor, which histologically resembled anaplastic astrocytoma, and received a course of radiation therapy and chemotherapy.
  • Increasing seizure frequency and expanding size on neuroimaging prompted a re-excision of the tumor.
  • The second resection was marked by islands of tissue resembling gray matter with slightly atypical neuronal and glial cells situated in the white matter.
  • Mild vascular proliferation and moderate nuclear pleomorphism also characterized the tumor.
  • P53 immunoreactivity was observed in approximately 40% of tumor cell nuclei.
  • This lesion is felt to represent a clinically aggressive glioneuronal neoplasm with an unusual and distinctive histologic phenotype.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology. Neuropil / pathology
  • [MeSH-minor] Adult. Antigens, Nuclear. Cell Nucleus / chemistry. Cell Nucleus / pathology. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen. Neovascularization, Pathologic / pathology. Nuclear Proteins / analysis. Reoperation. Synaptophysin / analysis. Treatment Outcome. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 by W.B. Saunders Company
  • (PMID = 11112223.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 0 / Synaptophysin; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


26. O'Brien DF, Farrell M, Delanty N, Traunecker H, Perrin R, Smyth MD, Park TS, Children's Cancer and Leukaemia Group: The Children's Cancer and Leukaemia Group guidelines for the diagnosis and management of dysembryoplastic neuroepithelial tumours. Br J Neurosurg; 2007 Dec;21(6):539-49
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Children's Cancer and Leukaemia Group guidelines for the diagnosis and management of dysembryoplastic neuroepithelial tumours.
  • Dysembryoplastic neuroepithelial tumours (DNETs) were incorporated into the new World Health Organization classification of brain tumours as part of the group of glioneuronal tumours in 1993.
  • Large series of patients with DNETs and pharmaco-resistant epilepsy have been reported.
  • DNETs are most often located in the temporal lobe, occurring in both mesial and lateral temporal locations.
  • DNETs have also been reported in the insular cortex, brain stem, cerebellum, occipital lobe and striatum.
  • DNETs associated with pharmaco-resistant epilepsy should be removed early to achieve seizure freedom and prevent tumour progression.
  • It is not advocated to use a stereotactic biopsy only, as this may generate an unrepresentative tissue sample consisting of an oligodendroglial component only and may lead to an incorrect diagnosis.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Neoplasms, Neuroepithelial / diagnosis. Neoplasms, Neuroepithelial / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnostic Imaging / methods. Drug Resistance, Neoplasm / physiology. Epilepsy / diagnosis. Epilepsy / therapy. Female. Humans. Infant. Infant, Newborn. Male. Practice Guidelines as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18071981.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 64
  •  go-up   go-down


27. Le BH, Sandusky M: 81 year-old male with confusion and weakness. Brain Pathol; 2010 Jul;20(4):867-70
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma, the most common primary brain tumor, is a highly infiltrative, malignant astrocytic neoplasm that demonstrates a wide spectrum of morphologic heterogeneity.
  • Cases with a primitive neuroectodermal tumor (PNET)-like component are rare, but are being increasingly recognized and studied.
  • This report presents an example of glioblastoma with a prominent primitive neuroectodermal-like component in an 81 year-old male who, during the course of concurrent chemotherapy and radiation therapy, died five weeks following initial diagnosis.
  • [MeSH-major] Brain Neoplasms / pathology. Confusion / pathology. Glioblastoma / pathology. Muscle Weakness / pathology. Neuroectodermal Tumors, Primitive / pathology. Temporal Lobe / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20626749.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


28. Bachmeyer C, Reynaert G, Pen L, Kazerouni F, Cazier A, Schwarz J: [Giant cutaneous squamous cell carcinoma of the nose with subsequent brain extension]. Ann Dermatol Venereol; 2004 Aug-Sep;131(8-9):791-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant cutaneous squamous cell carcinoma of the nose with subsequent brain extension].
  • INTRODUCTION: Cutaneous squamous cell carcinoma is an invasive and destructive tumor, and may cause death by local extension or because of metastasis.
  • We report the case of a patient with a giant squamous cell carcinoma of the nose and extension to the brain and discuss the main risk factors from this extension.
  • Histological examination disclosed a well-differentiated tumor and perineural involvement, with at least a 6 mm margin.
  • Whilst the patient was receiving chemotherapy, a second relapse occurred responsible for ophthalmoplegia and loss of vision, with involvement of the left orbital apex, cavernous sinus and temporal lobe.
  • DISCUSSION: Brain extension of cutaneous squamous cell carcinoma of the head is rare.
  • Main risk factors for such a poor course are discussed, including the size of tumor, the anatomic site, the depth and perineural invasion.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Nose Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15505546.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


29. Sakuma I, Tomura N, Omachi K, Takahashi S, Watarai J, Sasajima T, Mizoi K: [A case of astrocytoma with extracranial extension after malignant transformation]. No To Shinkei; 2003 Feb;55(2):153-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The initial magnetic resonance imaging (MRI) demonstrated a slightly hyperintense tumor on T 2-weighted images in the tip of the left temporal lobe, and no contrast enhancement on gadolinium-enhanced T 1-weighted images(Gd-T 1 WI).
  • On digital subtraction angiography, there was no tumor staining.
  • The initial diagnosis was made as low-grade astrocytoma.
  • MRI revealed a remarkably growing tumor with ring-like enhancement on Gd-T 1 WI.
  • She underwent a temporal lobectomy, which pathologically demonstrated a glioblastoma.
  • After surgery, chemotherapy and radiotherapy were performed.
  • The tumor invades the skull base and extended into the infratemporal fossa 25 months after surgery.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Glioblastoma / pathology. Skull Base Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12684996.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Jahraus CD, Friedman AH: Chemopotentiation by ultrafractionated radiotherapy in glioblastoma resistant to conventional therapy. Tumori; 2010 Sep-Oct;96(5):771-5
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemopotentiation by ultrafractionated radiotherapy in glioblastoma resistant to conventional therapy.
  • CASE AND METHODS: The case of an 82-year-old woman is described whose resected frontoparietal glioblastoma progressed through treatment administered according to standard methods.
  • With review board and patient approval, we continued her treatment using radiotherapy and temozolomide, but drastically modified the radiotherapy fractionation, administering 50 cGy twice daily on each of the first 5 days of a 14-day cycle.
  • RESULTS: This modified regimen resulted in regression of the contrast-enhancing areas of disease recurrence identified on MRI, and the patient survived approximately 6 months following recurrence of her disease, having received 5 cycles of additional therapy after prior full-dose treatment.
  • CONCLUSIONS: Ultrafractionated radiotherapy and concurrent temozolomide were efficacious and tolerable in this patient whose glioblastoma previously progressed through conventional treatment.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Dose Fractionation. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Aged, 80 and over. Disease Progression. Female. Frontal Lobe / pathology. Frontal Lobe / surgery. Humans. Magnetic Resonance Imaging. Temporal Lobe / pathology. Temporal Lobe / surgery. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21302627.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


31. Kanamori M, Kumabe T, Watanabe M, Tominaga T: Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma. Case report. J Neurosurg; 2007 Jul;107(1):185-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors present the case of a 51-year-old man who presented with an anaplastic astrocytoma and anaplastic oligodendroglioma that developed 6 years after subtotal resection of a central neurocytoma in his right lateral ventricle.
  • He had received neither radiation therapy nor chemotherapy after the original resection.
  • On readmission, neuroimaging revealed a mass in the right parietal lobe and a diffuse lesion in the right temporal lobe, insula, and corona radiata.
  • Histological examination revealed anaplastic oligodendroglioma in the parietal lobe and anaplastic astrocytoma in the insula.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neurocytoma / surgery. Oligodendroglioma / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures. Time Factors


32. Gallego JM, Barcia JA, Barcia-Mariño C: Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta Neurochir (Wien); 2007 Mar;149(3):261-5; discussion 265
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival.
  • We report three cases in whom patients with glioblastoma multiforme were implanted with fibrin glue-secured Gliadel after the lateral ventricles had been opened, and who later developed severe hydrocephalus leading to death.
  • Although Gliadel may be an important adjunct to treatment, opening of the ventricles during surgery as part of its application should be considered a contra-indication.
  • [MeSH-major] Antineoplastic Agents, Alkylating / toxicity. Brain Neoplasms / drug therapy. Carmustine / toxicity. Glioblastoma / drug therapy. Hydrocephalus / chemically induced. Temporal Lobe / surgery
  • [MeSH-minor] Adult. Aged. Astrocytoma / drug therapy. Astrocytoma / mortality. Astrocytoma / surgery. Chemotherapy, Adjuvant. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Drug Implants. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Reoperation. Ventriculostomy

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Hydrocephalus.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334672.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Drug Implants; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; U68WG3173Y / Carmustine
  •  go-up   go-down


33. Isobe K, Uno T, Kawakami H, Ueno N, Aruga T, Yasuda S, Hanazawa T, Okamoto Y, Ito H, Shigematsu N: Hyperfractionated radiation therapy for locoregionally advanced nasopharyngeal cancer. Jpn J Clin Oncol; 2005 Mar;35(3):116-20
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated radiation therapy for locoregionally advanced nasopharyngeal cancer.
  • OBJECTIVE: The purpose of this study is to clarify the efficacy and toxicity of hyperfractionated radiation therapy (RT) for patients with nasopharyngeal cancer (NPC).
  • They received hyperfractionated RT with a fraction size of 1.2 Gy, with a median tumor dose of 72 Gy (range 64.8-80.4).
  • During this study period, our institutional strategy for locoregionally advanced NPC included neoadjuvant or concurrent chemotherapy combined with hyperfractionated RT, and 17 patients received some forms of cisplatin-containing chemotherapy.
  • With regard to late sequelae, one patient developed grade 3 osteomyelitis, and one patient each developed grade 4 passage disturbance and laryngeal edema.
  • No patients experienced any grades of optic nerve injury or temporal lobe necrosis.
  • CONCLUSIONS: Hyperfractionated RT using 1.2 Gy per fraction, for a total dose of 72 Gy, produces a comparable treatment outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dose Fractionation. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Nutritional Support. Osteomyelitis / chemically induced. Pharyngitis / chemically induced. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15741300.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


34. Hadjipanayis CG, Kondziolka D, Gardner P, Niranjan A, Dagam S, Flickinger JC, Lunsford LD: Stereotactic radiosurgery for pilocytic astrocytomas when multimodal therapy is necessary. J Neurosurg; 2002 Jul;97(1):56-64
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for pilocytic astrocytomas when multimodal therapy is necessary.
  • OBJECT: The goal of this study was to examine the role of stereotactic radiosurgery in the treatment of patients with recurrent or unresectable pilocytic astrocytomas.
  • METHODS: During a 13-year interval, 37 patients (median age 14 years) required multimodal treatment of recurrent or unresectable pilocytic astrocytomas.
  • Tumors involved the brainstem in 18 patients, cerebellum in three, thalamus in five, temporal lobe in four, and parietal lobe in two, as well as the hypothalamus, optic tract, corpus callosum, insular cortex, and third ventricle in one patient each.
  • Diagnosis was confirmed with the aid of stereotactic biopsy in 12 patients, open biopsy in five, partial resection in eight, and near-total resection in 12.
  • Multimodal treatment included fractionated radiation therapy in 10 patients, stereotactic intracavitary irradiation of tumor in four, chemotherapy in two, cyst drainage in six, ventriculoperitoneal shunt placement in three, and additional cytoreductive surgery in four.
  • Tumor volumes varied from 0.42 to 25 cm3.
  • The median radiosurgical dose to the tumor margin was 15 Gy (range 9.6-22.5 Gy).
  • After radiosurgery, serial imaging demonstrated complete tumor resolution in 10 patients, reduced tumor volume in eight, stable tumor volume in seven, and delayed tumor progression in 12.
  • No procedure-related death was encountered.
  • Thirty-three (89%) of 37 patients are alive at a median follow-up period of 28 months after radiosurgery and 59 months after diagnosis.
  • Three patients died of local tumor progression.
  • Despite the favorable histological characteristics and prognosis usually associated with this neoplasm, an adverse location, recurrence, or progression of this disease requires alternative therapeutic approaches such as radiosurgery.
  • [MeSH-major] Astrocytoma / surgery. Astrocytoma / therapy. Brain Stem Neoplasms / surgery. Brain Stem Neoplasms / therapy. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Biopsy. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Cysts / surgery. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Radiotherapy / adverse effects. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12134933.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


35. Poon D, Yap SP, Wong ZW, Cheung YB, Leong SS, Wee J, Tan T, Fong KW, Chua ET, Tan EH: Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys; 2004 Aug 1;59(5):1312-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A repeat course of radiotherapy was given concurrently with cisplatin, with cisplatin/5-fluorouracil as consolidation treatment.
  • Significant morbidities were present, including cranial nerve palsies due to extensive recurrent local disease before treatment of the recurrence.
  • Only 3 patients developed systemic metastases.
  • Grade 3-4 acute toxicities included emesis (9%) and neutropenia (14%), and Grade 3-4 late toxicities consisted of temporal lobe necrosis (3%), cranial neuropathy (6%), and endocrine abnormalities (14%).
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / radiotherapy. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15275714.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement